Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: Currently available studies that fully analyse the metabolic parameters in patients with prolactinoma are scarce and discordant. The aim of this study was to evaluate the metabolic effects of cabergoline (CAB) treatment in patients with newly diagnosed prolactinoma in relation to disease control and CAB dosage.
Design: This is a retrospective clinical-based therapy analysis.
Patients: Forty-three patients with prolactinoma (eight men, 35 women), aged 33·65 ± 11·23 years, were evaluated metabolically at baseline and after 12 months of CAB treatment.
Measurements: Body mass index (BMI), systolic and diastolic blood pressure, waist circumference (WC), lipid profile, haemoglobinA1c (HbA1c), glucose and insulin levels (and their areas under the curve, AUC) after an oral glucose tolerance test, homoeostasis model assessment of insulin resistance (Homa-IR) index, insulin sensitivity index (ISI) Matsuda, oral disposition index (DIo) and visceral adiposity index (VAI) were measured at baseline and after 12 months of treatment.
Results: Twelve months of CAB reduced WC (P < 0·001), total (P = 0·001) and low-density lipoprotein \terol (P < 0·001), triglycerides (P = 0·024), fasting insulin (P < 0·001), AUCINSULIN (P < 0·001), HbA1c (P = 0·022), Homa-IR (P < 0·001) and VAI (P < 0·001), with a concomitant increase in high-density lipoprotein cholesterol (P < 0·001) and in ISI Matsuda (P < 0·001), regardless of the degree of reduction in prolactin levels. The patients receiving higher doses (>0·50 mg/week) of CAB showed lower BMI (P = 0·009), fasting insulin (P = 0·001), Homa-IR (P < 0·001) and VAI (P = 0·018) and higher ISI Matsuda (P = 0·002) and DIo (P = 0·011), compared with those on lower doses.
Conclusions: A significant metabolic improvement was observed in patients with prolactinoma after 12 months of CAB treatment, especially when higher doses were used, highlighting the importance of considering the metabolic profile in these patients and the role of active treatment with high CAB doses.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/cen.12204 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The clinicopathological PANOMEN-3 classification predicts pituitary adenoma prognosis: a real-world retrospective single center study of a surgically treated cohort.
Pituitary
September 2025
Facoltà Di Medicina E Chirurgia, Università Cattolica del Sacro Cuore, Rome, Italy.
Introduction: Pituitary adenomas (PAs) are generally benign neoplasms, though in rare cases may exhibit aggressive behavior. In 2024, the PANOMEN-3 workshop released a new clinical-pathological classification. The objective of this study was to examine the potential of the PANOMEN-3 classification to predict prognosis of PAs and guide treatment in our single center cohort of patients with PAs.
View Article and Find Full Text PDFIdentifying Hub Genes Associated with Sex Disparities in Prolactinomas.
Genet Test Mol Biomarkers
September 2025
Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Male patients with prolactinomas exhibit greater invasiveness, resistance to dopamine agonists, making treatment more challenging. This study aims to explore the potential different genes contributing to sex disparities in prolactinomas. Weighted gene co-expression network analysis and differential expressed genes analysis were performed to identify sex-related hub genes.
View Article and Find Full Text PDFCabergoline-induced prolactinoma treatment and subsequent estrogen-driven vascular smooth muscle tumorigenesis in a middle-aged female: A case report.
Int J Surg Case Rep
August 2025
Urology Department, Saint Luke's Episcopal Hospital, Ponce, Puerto Rico.
Introduction And Importance: Renal angioleiomyoma is an exceptionally rare benign tumor of smooth muscle origin, often discovered incidentally and easily mistaken for other differential diagnoses on imaging.
Case Presentation: We report the case of a 34-year-old Puerto Rican woman with a history of prolactinoma treated with cabergoline, who was found to have a right renal-adrenal mass on imaging. She underwent successful laparoscopic resection.
Pituitary apoplexy within a prolactin-secreting macroadenoma in a child: A rare clinical entity with radiological correlation.
Radiol Case Rep
November 2025
Department of Mother and Child Radiology-Chu Hassan Ii, Sidi Mohammed Ben Abdellah University, Hrazem Hospital Center, P.O. Box 1835 Atlas, Fez, Morocco.
Pituitary apoplexy is an uncommon but potentially fatal syndrome of the pituitary gland, caused by ischemia, hemorrhage, or necrosis that can occur with or without a pre-existing pituitary neuroendocrine tumor (PitNET), as reported during pregnancy and in lymphocytic hypophysitis. We present in this paper a case of an 11-year-old girl with pituitary apoplexy. Our patient experienced sudden deterioration in her left eye vision and a headache.
View Article and Find Full Text PDFUrinary incontinence as a novel and underrecognized clinical manifestation of prolactinoma in women.
Pituitary
August 2025
Ankara Etlik City Hospital, Department of Endocrinology and Metabolism, Ankara, Turkey.
Objective: Prolactin exerts numerous pleiotropic effects on various tissues, including smooth muscle. Urinary incontinence, particularly the urge subtype, is primarily associated with detrusor overactivity-the involuntary contractions of the bladder's smooth muscle. The aim of this study is to investigate the potential impact of prolactinoma on urinary incontinence (UI) in women.
View Article and Find Full Text PDF